MPE has developed a series of factsheets for patients and patient advocates covering treatment for myeloma and AL amyloidosis. These publications contain essential information about treatments and medicines, so that patients can feel safe and informed when asking their doctor specific questions. There is also a PDF version with all the information available to download. Check out the following factsheets on:
Factsheets
Melphalan flufenamide
Melphalan flufenamide is derived from the chemotherapeutic agent melphalan. It is indicated for treating adult myeloma patients with dexamethasone.
Ciltacabtagene autoleucel
Ciltacabtagene autoleucel (also known as cilta-cel or Carvykti®) is a chimeric antigen receptor T-cell therapy (CAR T-cell therapy).
Thalidomide
Thalidomide is approved in combination with melphalan and prednisone (VMp) in patients with newly diagnosed myeloma.
Lenalidomide
Lenalidomide is a cancer medicine approved in Europe in 2007 for the treatment of myeloma.
Bortezomib
Bortezomib is a cancer medicine approved in Europe in 2012 for the treatment of adult patients with myeloma.
Daratumumab
Daratumumab is a monoclonal antibody approved in Europe since 2016 for use in myeloma patients.
Carfilzomib
Carfilzomib is a cancer medicine approved in Europe in 2015 for the treatment of relapsed and/or refractory myeloma.
Amyloidosis
Amyloidosis refers to a group of diseases characterised by the accumulation of an abnormal protein called amyloid, which builds up in tissues and organs.
Belantamab mafodotin
Belantamab mafodotin is a first-in-class antibody drug conjugate approved in Europe in 2020 for use in myeloma patients.
Stem cell transplant
Myeloma is a rare cancer of the bone marrow. It is due to the formation of abnormal plasma cells, also called myeloma cells, which divide uncontrollably.
These factsheets contain
essential information about
treatments and medicines.
Also there is a PDF with all
the info for each factsheet
These factsheets contain
essential information about
treatments and medicines.
Also there is a PDF with all
the info for each factsheet
Subscribe to
our newsletter!